AR and cancer: AZD5069 recognised by CXCR2 could improve the lack of the tumour suppressor phosatase and tensin homolog(PTEN), which can inhibit cancer cell survival through the inactivation of aldose reductase(AR), hypoxia induced factor‐1(HIF‐1) and nuclear factor‐kappa B(NF‐κB) transcription factors.